These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 31351173)

  • 21. Tau and Alpha Synuclein Synergistic Effect in Neurodegenerative Diseases: When the Periphery Is the Core.
    Vacchi E; Kaelin-Lang A; Melli G
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein.
    Quint WH; Matečko-Burmann I; Schilcher I; Löffler T; Schöll M; Burmann BM; Vogels T
    J Alzheimers Dis; 2021; 80(2):813-829. PubMed ID: 33579845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
    Yokota O; Terada S; Ishizu H; Tsuchiya K; Kitamura Y; Ikeda K; Uéda K; Kuroda S
    Acta Neuropathol; 2002 Oct; 104(4):333-41. PubMed ID: 12200618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases.
    Nonaka T; Watanabe ST; Iwatsubo T; Hasegawa M
    J Biol Chem; 2010 Nov; 285(45):34885-98. PubMed ID: 20805224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.
    Melki R
    J Parkinsons Dis; 2015; 5(2):217-27. PubMed ID: 25757830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons.
    Colla E; Panattoni G; Ricci A; Rizzi C; Rota L; Carucci N; Valvano V; Gobbo F; Capsoni S; Lee MK; Cattaneo A
    Neurobiol Dis; 2018 Mar; 111():36-47. PubMed ID: 29246724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.
    Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
    Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
    J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha-synuclein misfolding and neurodegenerative diseases.
    Uversky VN
    Curr Protein Pept Sci; 2008 Oct; 9(5):507-40. PubMed ID: 18855701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies.
    Martinelli AHS; Lopes FC; John EBO; Carlini CR; Ligabue-Braun R
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-aggregation Effects of Phenolic Compounds on α-synuclein.
    Ono K; Tsuji M; Yamasaki TR; Pasinetti GM
    Molecules; 2020 May; 25(10):. PubMed ID: 32456274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A glimpse into the structural properties of α-synuclein oligomers.
    Santos J; Pallarès I; Ventura S
    Biofactors; 2024; 50(3):439-449. PubMed ID: 38063360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.
    Katsinelos T; Tuck BJ; Mukadam AS; McEwan WA
    Front Immunol; 2019; 10():1139. PubMed ID: 31214163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining the Protein Seeds of Neurodegeneration using Real-Time Quaking-Induced Conversion Assays.
    Manca M; Kraus A
    Biomolecules; 2020 Aug; 10(9):. PubMed ID: 32854212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interface between tauopathies and synucleinopathies: a tale of two proteins.
    Galpern WR; Lang AE
    Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of native α-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells.
    Dettmer U; Ramalingam N; von Saucken VE; Kim TE; Newman AJ; Terry-Kantor E; Nuber S; Ericsson M; Fanning S; Bartels T; Lindquist S; Levy OA; Selkoe D
    Hum Mol Genet; 2017 Sep; 26(18):3466-3481. PubMed ID: 28911198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.